Enovix Corporation vs Roivant Sciences Ltd. Common Shares — how do they compare? Enovix Corporation trades at $2.51 (market cap $561.79M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 44.7× Enovix Corporation's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| ENVX | ROIV | |
|---|---|---|
Market Cap | $561.79M | $25.09B |
Volume | 5,898,906 | 5,738,571 |
Sector | Industrials | Health |
52-Week High | $13.19 | $41.81 |
52-Week Low | $2.50 | $16.04 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $623.49M | $21.36B |
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →